Humacyte Third Quarter 2026 Earnings Conference Call - HUMACYTE INC

Explicit Guidance:

• Revenue Growth: No formal quantitative guidance provided; however, management explicitly expects fourth-quarter 2026 sales to "at least double" the Q3 2026 result of $1 million (projecting ~$2M+ for Q4), driven by momentum and hospital adoption.
• Gross Margin/Cost Structure: Management does not expect positive gross margins in Q4 2026 due to continued allocation of overhead costs related to unused production capacity. A "robust production schedule" for 2027 is anticipated to eliminate unused capacity costs, implying a path to positive margins in 2027.
• Cash Flow: No specific cash burn or runway guidance provided; however, net cash used in operations is expected to decline further in 2027 due to reduced inventory production costs and the phasing out of unused capacity overhead.
• R&D Spend: R&D expenses are expected to continue declining sequentially in 2026; resources allocated to the "biovascular pancreas" project will likely increase in 2027 contingent on improved cash flow visibility.

Business-Segment Outlook:

• Symbio/Vest (Vascular Injury): Sales accelerated 151% QoQ in Q3 2026 to >$1M; hospital adoption increased 44% (34 to 49 sites). 20+ new hospitals are expected to place orders by year-end 2026. Commercial momentum is projected to continue through 2027.
• ATEV (Dialysis Access): Supplemental BLA (SBLA) submission scheduled for November 2026. If FDA accepts filing in January 2027 and grants Priority Review, PDUFA date is expected in May 2027 with commercial launch in June 2027. Without Priority Review, launch delayed to September/October 2027.
• CTEV (Coronary Artery Bypass Grafting): Phase IIa clinical study initiated in October 2026; patient screening is open. First commercial-scale manufacturing lot completed.
• Market Opportunity: Dialysis access addressable market estimated at $2–$3 billion annually in the US (500k patients, 100k new entries/year).
• International Expansion: MAA application in Israel under active review; other Middle East opportunities being evaluated. Vascular trauma uptake expected to grow organically as surgeons transition from planned cases to emergency trauma use.

Market and Competitive Outlook:

• Adoption Dynamics: Surgeon adoption follows an organic progression from planned daylight surgeries to emergency trauma scenarios. Existing vascular surgeons are the primary growth vector for both trauma and upcoming dialysis indications (estimated 80% overlap).
• Pricing: Average unit price (list) ~$17,000; introductory/evaluation pricing used in new healthcare systems is expected to diminish as ASP strengthens through Q4 2026 and into 2027.
• Competitive Moat: No new off-the-shelf conduits introduced for CABG in the US in 40 years; ATEV positioned as a first major advance in dialysis access in decades.

Macro / Industry Outlook:

• Regulatory/Reimbursement: Focus on CMS reimbursement and value-based care models (e.g., Kidney Care Choices Model). Strategic partnerships with value-based organizations to demonstrate impact on "optimal start" metrics (avoiding catheters) and total cost of care reduction.
• Data Generation: Additional long-term data publications from VO7 and VO12 Phase III studies expected prior to FDA approval; follow-up on VO12 extends to Year 2.
• Strategic Personnel: Two nephrology advisors (Drs. Roy Chowdhury and Kosman) engaged to refine reimbursement, market access, and peer-to-peer education strategies for dialysis launch.

Strategic Initiatives:

• Commercial Transformation: Remodeled commercial team with deep vascular surgery relationships; refined pricing incentives and peer-to-peer education launched Q2/Q3 2026.
• Pipeline Focus: Near-term (2026-early 2027) focus on commercializing Symbio/Vest and ATEV launch preparation; biovascular pancreas project deprioritized until 2027 when cash flow stability improves.
• Capacity Building: Completion of first commercial-scale CTEV manufacturing lot; ramp-up of production schedule planned for 2027 to support sales growth and absorb overhead.

Risks and Headwinds to Outlook:

• Regulatory Uncertainty: Potential delay in ATEV launch if FDA does not grant Priority Review (PDUFA pushed from May to September 2027).
• Production Overhead: Continued negative impact on gross margin in Q4 2026 from unused production capacity costs; resolution dependent on ramping production volumes in 2027.
• Adoption Pacing: Growth trajectory dependent on surgeon education curves and transition to trauma applications.
• Litigation: Reserves for shareholder litigation and legal costs remain a variable in G&A expenses (noted $0.6M net expense in prior quarter).

Management Tone on the Future:

• Confidence Level: Highly confident and optimistic; described Q3 as an "inflection point" and "turning point" for the company.
• Forward Outlook: Explicit statement that "next quarter and then 2027 are going to have a lot more growth."
• Strategic Sentiment: Emphasis on "sustained growth," "value creation," and the belief that the revamped commercial execution is delivering dividends faster than anticipated.